Efficacy and Safety of Low Dose Recombinant Tissue-Type Plasminogen Activator for the Treatment of Acute Pulmonary Thromboembolism: A Randomized, Multicenter, Controlled Trial

BACKGROUND: Optimal dosing of the recombinant tissue-type plasminogen activator (rt-PA) is important in treating pulmonary thromboembolism (PTE). The aim of this study was to compare the efficacy and safety of a 50 mg/2 h rt-PA regimen with a 100 mg/2 h rt-PA regimen in patients with acute PTE. METH...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chen, Zhai, Zhenguo, Yang, Yuanhua, Wu, Qi, Cheng, Zhaozhong, Liang, Lirong, Dai, Huaping, Huang, Kewu, Lu, Weixuan, Zhang, Zhonghe, Cheng, Xiansheng, Shen, Ying H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American College of Chest Physicians. Published by Elsevier Inc. 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126994/
https://www.ncbi.nlm.nih.gov/pubmed/19741062
http://dx.doi.org/10.1378/chest.09-0765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126994/
https://www.ncbi.nlm.nih.gov/pubmed/19741062
http://dx.doi.org/10.1378/chest.09-0765

Ejemplares similares